Marcadia, Roche deal

The Federal Trade Commission granted early termination to the waiting period under the Hart-Scott-Rodino Act for a proposed acquisition of diabetes and obesity company Marcadia by Roche. Further details were not disclosed. Neither company could be reached for comment. Under Hart-Scott-Rodino, companies are required to file premerger notification and wait for government review of a potential large merger or acquisition. If the waiting period expires or is terminated, the companies are free to close their deal.

Marcadia's lead compound is MAR701, a dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which is in Phase I testing for Type II diabetes. ...